Nano Sb{sub 2}O{sub 3} catalyzed green synthesis, cytotoxic activity, and molecular docking study of novel α-aminophosphonates
Journal Article
·
· Medicinal Chemistry Research (Print)
- Sri Venkateswara University, Department of Chemistry (India)
- Sri Venkateswara University, Department of Bio-Chemistry (India)
Green synthesis of a series of novel dialkyl (aryl substituted)(2-fluoro-4-((2-methylcarbamoyl)pyridine-4-yl)oxy)phenyl)amino)methyl)phosphonates is accomplished by a simple and an efficient one pot three component reaction of 3-(4-amino-3-fluorobenzyl)-N-methylbenzamide with different substituted aromatic aldehydes and dialkyl phosphite in the presence of nano Sb{sub 2}O{sub 3} catalyst under solvent free conditions at 40–50 °C to obtain the title compounds. Excellent isolated product yields are obtained (85–95%) with high purity within shorter reaction times (30–60 min). The title compounds are characterized by IR, {sup 1}H, {sup 13}C, {sup 31}P-NMR and mass spectral data. The synthesized compounds are screened for their anticell-proliferation activity on seven cell lines, Control cells–HEK293 (human embryonic kidney), DU-145 (human prostate adenocarcinoma), MCF-7 (human ER+/PR+/Her2− breast cancer), MDA-MB-231 (human ER−/PR−/Her2− breast cancer), Mia-Paca-2 (human pancreatic carcinoma), HeLa (human cervical cancer) cells as well as HepG2 (human hepatocellular carcinoma) cancer cell lines using Sulforhodamine B (SRB) assay method. Docking studies were carried out for all these synthesized compounds against topoisomerase-II by using Auto dock method. Doxorubicin was taken as standard. Compounds 4a, 4c, 4d, 4e, 4h, 4i, 4k, and 4l exhibited higher cytotoxic activity than the standard doxorubicin. .
- OSTI ID:
- 22936203
- Journal Information:
- Medicinal Chemistry Research (Print), Journal Name: Medicinal Chemistry Research (Print) Journal Issue: 4 Vol. 28; ISSN 1054-2523
- Country of Publication:
- United States
- Language:
- English
Similar Records
Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity
Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer
Journal Article
·
Wed Dec 20 19:00:00 EST 2017
· Oncotarget
·
OSTI ID:1629899
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity
Journal Article
·
Sun Jul 01 00:00:00 EDT 2012
· Toxicology and Applied Pharmacology
·
OSTI ID:22215342
Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer
Journal Article
·
Sun Aug 01 00:00:00 EDT 2010
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21436101